Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease

{
  "signal_id": "38da1cc2-ce9d-9d8e-b092-bf1f24378208",
  "signal_type": "news",
  "signal_subtype": "recognized_as",
  "detected_at": "2026-08-31T23:30:00+00:00",
  "company": {
    "name": "Biogen",
    "domain": "biogen.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/08/31/3353756/0/en/canada-s-drug-agency-issues-final-positive-recommendation-supporting-public-reimbursement-of-leqembi-lecanemab-for-early-alzheimer-s-disease.html",
    "title": "Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease",
    "excerpt": "TOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that Canada’s Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of LEQEMBI ® (lecanemab) for eligible patients in Canada living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (early AD). The final recommendation follows a reconsideration by CDA-AMC and is an important step toward access to LEQEMBI. Next steps include negotiations through the pan-Canadian Pharmaceutical Alliance (pCPA), followed by individual reimbursement decisions by public drug plans in Canada’s provinces and territories. More than 770,000 people in Canada were estimated to be living with dementia in 2025, and the number of people living with dementia in Canada is projected to increase to 1.7 million by 2050.¹ Eisai serves as the lead for lecanemab’s development and regulatory submissions globally, with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. Notes to Editors References",
    "product": "LEQEMBI",
    "summary": "Biogen's drug LEQEMBI® (lecanemab) received a final positive recommendation supporting public reimbursement for early Alzheimer’s disease from Canada’s Drug Agency (CDA-AMC).",
    "location": "Canada",
    "planning": false,
    "image_url": "https://ml.globenewswire.com/Resource/Download/80f9c524-3da2-4583-a763-0dad931fa182",
    "confidence": 0.9,
    "recognition": "Final positive recommendation supporting public reimbursement",
    "product_data": {
      "name": "LEQEMBI",
      "full_text": "LEQEMBI ® (lecanemab)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-08-31T23:30:00Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "Canada",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-08-31",
    "article_sentence": "Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that Canada’s Drug Agency (CDA-AMC) has issued a final recommendation supporting public reimbursement of LEQEMBI ® (lecanemab) for eligible patients in Canada living with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (early AD).",
    "related_company_name": "Canada’s Drug Agency",
    "related_company_domain": "cda-amc.ca"
  }
}

curl https://signals.autobound.ai/v1/signals/38da1cc2-ce9d-9d8e-b092-bf1f24378208 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"biogen.com","limit":20}'